A r t i c l e s ALL arising in infants less than 1 year of age accounts for 2.5-5% of all childhood ALL. Up to 80% of infant ALL cases are characterized by rearrangements of the MLL gene (encoding mixed-lineage leukemia) at 11q23 (also called KMT2A) 1,2 . Although current event-free survival rates for childhood ALL have reached greater than 85% (ref. 3), the outcome for infant ALL with MLL-R remains poor, with an event-free survival of only 28-36% (refs. 1-3). Thus, new therapeutic approaches are needed to improve cure rates for these patients. Studies on this leukemia subtype have demonstrated that the MLL translocation often occurs in utero and that clinically overt leukemia develops with a very short latency, with rare cases presenting at birth 4,5 . These observations suggest that MLL-R ALL requires few additional mutations to induce full transformation. Consistent with this hypothesis, genome-wide studies on MLL-R ALL using SNP arrays have shown that this leukemia subtype contains on average only one copy number alteration (CNA) per case 6,7 . Nevertheless, mouse models of MLL-R leukemia suggest that expression of the MLL chimeric gene alone is insufficient for full transformation 8 . To gain a better understanding of the complete landscape of somatic mutations in infant MLL-R ALL, we performed a genome-wide analysis on this leukemia subtype as part of the St. Jude Children's Research HospitalWashington University Pediatric Cancer Genome Project (PCGP) 9 .
A r t i c l e s blood cells from a discovery cohort of 22 infants with MLL-R ALL (Supplementary
, and Supplementary Tables 1 and 2). The leukemic genomes had an average haploid coverage of 39×. Somatic alterations, including single-nucleotide variations (SNVs), insertionsdeletions (indels), structural variations and CNAs, were detected using multiple analytical pipelines 10, 11 and validated using orthogonal DNA sequencing approaches (Online Methods).
Whole-genome sequencing showed that the infant MLL-R ALL genomes contained an average of 111 somatic sequence mutations (range of 29-229) and 10 CNAs or structural variations (range of 2-26) per case ( Supplementary Fig. 2 and Supplementary Tables 3 and 4), yielding a median somatic coding mutation rate of 7.30 × 10 −8 mutations per base (range of 0 to 2.29 × 10 −7 ). With the exception of pediatric low-grade glioma 12 , this rate is 2-to 180-fold lower than contained a balanced t(11;19)(q23;p13.3) with the break on chromosome 19 occurring 22.7 kb 5′ of MLLT1, resulting in a spliced (as indicated by the asterisk) in-frame MLL-MLLT1 chimeric gene. The translocation had an inverted intrachromosomal duplication spanning 0.3 kb at the breakpoint on chromosome 19 that resulted in an out-of-frame RFX2-MLL fusion. In addition, an unrelated intrachromosomal deletion of 46 bp was detected on chromosome 6. (c) INF004 contained a complex three-way translocation involving chromosomes 9, 10 and 11 that encoded an MLL-MLLT10 fusion gene on the derivative chromosome 11, an out-of-frame MLLT10-CNTNAP3B chimeric gene on chromosome 9 and 3′-truncated MLL on chromosome 10. This case also contained a t(8;14)(q24;q11.2) that resulted in the juxtaposition of MYC with the TRA locus (encoding T cell receptor α), as denoted by the caret. In addition, a non-silent SNV in COL13A1 and a deletion on chromosome 9 disrupted PAX5. LOH, loss of heterozygosity; SV, structural variation. (d) Structure of the INF004 complex translocation involving chromosomes 9p11 (blue), 10p12 (yellow) and 11q14-23 (burgundy). Genomic coordinates (hg18) are indicated above each genomic segment. The MLL-MLLT10 fusion gene is depicted by the solid arrow; all other rearrangements are depicted by dotted arrows. Copy number gains (red) and losses (blue) at the respective breakpoints are shown. The final genomic products on chromosomes 9, 10 and 11 are shown in supplementary Figure 9 . Ter, terminus; Cen, centromere.
the rates reported in adult and pediatric cancers (Supplementary Table 5 ). The mutation spectrum across the cohort did not suggest any specific mutational mechanisms, with the most common nucleotide changes being C>T/G>A transitions ( Supplementary Fig. 2 ). The number of somatic alterations affecting the coding region of annotated genes or regulatory RNAs averaged 8.2 alterations/case, including 2.2 non-silent SNVs (range of 0-4) and 6.0 CNAs or structural variations (range of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] per case (Fig. 1a-c, Supplementary Figs. 2 and 3 , and Supplementary Tables 3, 4 and 6-8). RNA sequencing (RNA-seq) in 21 of 22 cases demonstrated that 48% of the non-silent SNVs were expressed ( Supplementary Figs. 4 and 5, and Supplementary Tables 9-11). Despite the paucity of mutations, 81% of the expressed missense mutations were predicted to have a deleterious effect on protein function.
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Notably, the majority of the CNAs and structural variations were a direct consequence of the MLL rearrangement, with the breakpoint of both MLL and its partner gene typically accompanied by the gain or loss of adjacent genetic material (Fig. 1d) . When the MLL-related CNAs and structural variations were removed from consideration, the average number of CNAs and structural variations per case decreased to 3.0 (Supplementary Table 12 ). Additionally, we detected 40% of the identified somatic SNVs at a mutant allele frequency (MAF) below 30% despite the high tumor purity (average of 92%, range of 74-100%; Supplementary Tables 1, 4, 8 and 13 ). This suggests that these mutations reside in minor diagnostic subclones. We confirmed this hypothesis by performing custom capture and deep sequencing at an average coverage of 437× for all the tier 1-3 somatic mutations identified in five cases. This analysis demonstrated the presence of substantial intratumoral heterogeneity (Supplementary Figs. 6  and 7) . If we focused only on the mutations (including SNVs and indels) present in the dominant leukemic clone, the average number of non-silent mutations decreased to 1.3 mutations/case (Supplementary Table 13) , with only 0.6 expressed at the RNA level ( Supplementary  Fig. 5 and Supplementary Table 11) . A direct comparison of these mutation frequencies to those observed across 29 human cancers showed infant ALL to have one of the lowest frequencies of somatic mutation (Supplementary Fig. 8 ) [13] [14] [15] .
The majority of MLL rearrangements are unbalanced Whole-genome sequencing detected a total of 133 structural variations and CNAs across the infant ALL cohort affecting annotated genes (Supplementary Tables 3, 7 , 12 and 14, and Supplementary Note). Approximately half (n = 67) of the 133 structural variations and CNAs were a direct result of the MLL rearrangement. Within the remaining half (n = 66), the most frequently affected genes were PAX5 (five cases), CDKN2A/CDKN2B (three cases) and the noncoding RNA genes DLEU1/DLEU2 (three cases). The structural variations and CNAs affecting these genes were predicted to result in loss of function of a single allele.
Consistent with previous studies [16] [17] [18] [19] , more than half of the MLL rearrangements were complex, involving three or more chromosomes and/or accompanied by large insertions, deletions and/or inversions of sequences adjacent to the breakpoints (Fig. 1d, Supplementary Figs. 3 and 9-16, and Supplementary Table 8) . Moreover, even so-called simple cytogenetically balanced MLL translocations that involved only two chromosomes were found at the base-pair level to have focal deletions and/or insertions of sequences at the breakpoints (Supplementary Table 15 ). As a result, although each MLL rearrangement was predicted to encode an in-frame MLL-partner gene fusion protein, only 10 of 22 of the analyzed cases were predicted to encode an in-frame reciprocal partner gene-MLL fusion protein. RNA-seq on available samples demonstrated that six of nine cases with a predicted reciprocal fusion expressed the reciprocal product, consistent with previous reports (Supplementary Tables 16 and 17 ) 20 . Two of the predicted in-frame reciprocal fusion proteins involved genes with a known role in cancer: KRAS-MLL and AFF1-RAD51B-MLL ( Supplementary Figs. 11 and 12, and Supplementary Table 17) . Some of the complex MLL rearrangements also resulted in alterations of genes adjacent to MLL and/or the MLL partner gene (Supplementary Table 16 ). An analysis Table 25 ). The tyrosine kinase-PI3K-RAS pathway mutations were observed in association with each of the different types of MLL rearrangements identified in infant ALL (Fig. 2b) . In every case analyzed by RNA-seq, the activating mutant alleles were expressed, irrespective of their MAFs ( Fig. 2b and Supplementary Table 26 ). The majority of the identified tyrosine kinase-PI3K-RAS pathway mutations have previously been shown to be activating mutations (or inactivating mutations in the case of the homozygous deletion of NF1 in INF018) [22] [23] [24] [25] [26] [27] [28] [29] . However, two cases contained a FLT3 mutation encoding p.Asn676Lys that was previously reported in an acute myeloid leukemia (AML) case after the development of resistance to the kinase inhibitor PKC412 (refs. 30,31) and as a recurrent mutation in core binding factor leukemia 32 ( Supplementary Fig. 24 and Supplementary Note). Similarly, we identified two cases that contained new PIK3R1 mutations, including an internal tandem duplication in the inter-SH2 domain (PIK3R1-ITD) ( of the sequence surrounding the breakpoints of MLL and its partner genes suggested that the predominant mechanism of rearrangement involved non-homologous end joining 21 .
We performed RNA-seq on an additional 12 diagnostic MLL-R cases from a validation cohort of infant MLL-R ALL and identified a new MLL fusion gene partner, USP2 (encoding ubiquitin-specific peptidase 2), located at 11q23.3, approximately 1 Mb from MLL on the reverse strand ( Supplementary Fig. 17 and Supplementary Table 17) . RNA-seq also identified two new non-MLL in-frame fusion genes in INF016, CABIN1-TRAPPC10 and PAX5-KANK1 (Supplementary  Table 17) , as well as an out-of-frame DDTL-CABIN1 fusion. Upon manual review, we identified CABIN1-TRAPPC10 and DDTL-CABIN1 fusions in very few whole-genome sequencing reads, whereas the PAX5-KANK1 fusion lacked any whole-genome sequencing reads, suggesting that these fusions were present in minor subclones.
Mutations in tyrosine kinase-PI3K-RAS signaling pathways
Despite the paucity of somatic mutations in the discovery cohort, we observed activating mutations in tyrosine kinase-phosphoinositide 3-kinase (PI3K)-RAS pathways, with recurrent mutations in KRAS (n = 4) and NRAS (n = 2) and non-recurrent mutations in FLT3, NF1, PTPN11 and PIK3R1 (Supplementary Tables 6 and 8). In contrast to the non-silent SNVs, where only 48% of the mutant alleles were expressed, 100% of the activating kinase-PI3K-RAS pathway mutant alleles were expressed ( Supplementary Fig. 5 and Supplementary  Table 11 ). To extend these results, we sequenced the exons of 232 genes that included all mutated genes identified in the discovery cohort, as well as other genes in kinase-PI3K-RAS signaling pathways (for a list of the sequenced genes, see the Supplementary Note), in a validation cohort consisting of an additional 43 infant ALL cases, of which 25 harbored an MLL rearrangement. Each sample was also analyzed for CNAs by SNP arrays (Online Methods and Supplementary Tables 18-23) . Recurrent mutations were identified in 21 genes or gene loci across the npg VOLUME 47 | NUMBER 4 | APRIL 2015 Nature GeNetics A r t i c l e s A surprising observation was that 65% (20/31, observed in 22 cases) of the activating tyrosine kinase-PI3K-RAS pathway mutations had MAFs <30%, suggesting that they were present in minor subclones (Supplementary  Tables 25 and 27 , and Supplementary Note). Moreover, although eight cases contained two or more mutations in this pathway, the MAF for each mutation was below 30% in six cases. To further explore the importance of the identified tyrosine kinase-PI3K-RAS pathway mutations, we analyzed seven matched diagnostic and relapse infant MLL-R samples, including five with a mutation in this pathway at diagnosis. Although the MAF of the activating mutation was maintained or increased at relapse in two cases (INF001 and INF65), the mutations were lost in two other cases (INF033 and INF042) and, in another case (INF073), the MAF for the PIK3CA mutation decreased from 39% to 15% (Supplementary  Table 28 ). These data suggest that activating mutations in tyrosine kinase-PI3K-RAS pathways may not be necessary for the maintenance of leukemic cells.
Although we observed a trend toward poorer event-free survival and overall survival and an increased cumulative incidence of relapse in patients harboring an activating pathway mutation, these trends did not reach statistical significance (Supplementary Fig. 30 ). There was no difference in the age at diagnosis of infant MLL-R cases with or without an activating mutation (Supplementary Fig. 31 ). However, within the infant cohort positive for the MLL-AFF1 fusion (n = 23), those with an activating mutation were on average younger at diagnosis than those lacking a mutation (mean of 4.01 versus 6.75 months, P = 0.0473; Supplementary Fig. 32a ). Furthermore, there was an age difference among patients with activating mutations in a major or minor clone and those lacking an activating mutation (means of 2.77, 5.09 and 6.75 months, respectively, P = 0.0228; Supplementary  Fig. 32b ), suggesting that an activating mutation among MLL-AFF1-positive patients may be associated with decreased disease latency.
Clonal evolution at relapse in infant MLL-R ALL
To further explore the relationship between diagnosis and relapse in infant MLL-R ALL, we compared all somatic mutations identified in the diagnostic and relapse samples for two infant patients with MLL-R ALL, each relapsing 3 years after diagnosis (INF001D/INF001R and INF002D/INF002R). We analyzed non-tumor as well as diagnostic and relapse samples by whole-genome sequencing followed by custom capture enrichment and deep sequencing, allowing us to accurately calculate the MAFs for all SNVs in each leukemia. In both cases, similarly to non-MLL-R leukemia, relapse was associated with a marked increase in the total number of SNVs and CNAs or structural variations (Fig. 3a,b, Supplementary Figs. 
33-35, and Supplementary Tables 3, 29 and 30).
We analyzed the SNVs occurring in unique sequences outside of genes or gene regulatory regions (tier 3 SNVs) at diagnosis and relapse for each case by assigning them to clusters with the highest probability on the basis of their MAFs (Online Methods). We identified five mutation clusters in INF002 at diagnosis with MAFs of 0.426, 0.236, 0.114, 0.058 and 0.024 (Fig. 3c,d) . The diagnostic mutations with a MAF of 0.426 are consistent with heterozygous mutations present in every leukemic cell, whereas clusters with lower MAFs represent mutations present in minor subclones. After adjusting for tumor purity, the diagnostic sample was predicted to contain five related clones with 6.25-50% population frequencies. At relapse, the majority of tier 3 mutations occurred at a MAF of 0.5, suggesting the presence of a single clone descending from a minor clone present as 6.25% of the diagnostic sample. The results for INF001 followed the same trend (Supplementary Fig. 33) . In both cases, the founder clone at relapse acquired additional mutations after treatment, although the mutation spectrum did not differ substantially between the diagnostic and relapse samples for these two patients (Supplementary Fig. 36 ). SJINF002  SJINF003  SJINF004  SJINF005  SJINF006  SJINF007  SJINF008  SJINF009  SJINF010  SJINF011  SJINF012  SJINF013  SJINF014  SJINF015  SJINF016  SJINF017  SJINF018  SJINF019  SJINF020  SJINF021  SJINF022  SJMLL001  SJMLL002  SJMLL003  SJMLL004  SJMLL005  SJMLL006  SJMLL008  SJMLL009  SJMLL010  SJMLL011  SJMLL012  SJMLL013  SJMLL014  SJMLL016  SJMLL017  SJMLL018  SJMLL019  SJMLL020  SJMLL021 Figure 4 Mutational profiles of infant and non-infant MLL-R leukemia. (a) The number of non-silent SNVs and indels in the dominant leukemic clone affecting annotated genes in infant MLL-R ALL and non-infant MLL-R leukemia. (b) Distributions of somatic SNVs, indels and CNAs in epigenetic regulatory genes in infant MLL-R ALL and non-infant MLL-R leukemia demonstrating that these genes are mutated significantly more often in non-infant MLL-R leukemia (two-sided Fisher's exact test, P = 0.04). The black line between SJMLL002 and SJMLL021 indicates the separation between the lymphoblastic and myeloid non-infant leukemias. The only gene mutation that was found not to be expressed at the detection limit of our RNA-seq analysis was the one in L3MBTL3.
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Genomic landscape of infant non-MLL-R ALL
We also performed targeted gene resequencing of the 232 genes and SNP arrays on 18 infant non-MLL-R ALLs (Online Methods and Supplementary Tables 18 and 21-23) . There was no significant difference in the average number of SNVs in these 232 genes or in the frequency of tyrosine kinase-PI3K-RAS pathway mutations between infant MLL-R (22/47, 47%) and infant non-MLL-R (7/18, 39%) ALL (P = 0.59); again, all activating mutations were expressed in the 6 cases subjected to RNA-seq. In contrast to SNVs, CNAs were found significantly more often in infants lacking an MLL rearrangement than in infants with MLL rearrangements (average of 2.2/case versus 1.0/case); however, this increased frequency was associated with age and was independent of the presence or absence of the MLL rearrangement (P = 0.005; Supplementary Figs. 37-39) . CDKN2A/CDKN2B deletions were more frequent in the infant non-MLL-R cases, approaching the frequency seen in standard non-Philadelphia-positive childhood ALL (5/18, 28% versus 4/47, 8.5%, P = 0.058) 33 .
Six of the 18 non-MLL-R infant cases had RNA available for sequencing, 4 of which carried either newly identified fusion genes and/or altered genes that would be predicted to encode truncated proteins (Supplementary Table 17 ). Specifically, we identified two new fusions containing NUTM1: BRD9-NUTM1 (INF049) and ACIN1-NUTM1 (INF074). The BRD9-NUTM1 fusion product created by t(5;15)(p15;q14) consisted of the first 14 exons of BRD9 fused to exons 3-8 of NUTM1. This newly identified fusion is analogous to the BRD3-NUTM1 and BRD4-NUTM1 fusions found in midline carcinomas 34 . The patient we analyzed was described as having a t(5;15)(p15;q12), which is a previously reported cytogenetic finding in infant non-MLL-R ALL; the BRD9-NUTM1 fusion may thus be recurrent in infants with t(5;15)(p15;q11-13) 35, 36 . The ACIN1-NUTM1 fusion involved the same exons of NUTM1 fused to the first four exons of ACIN1 at 14q11. The patient we analyzed had an ins(15;14)(q22;q1 1.2q32.1), by conventional karyotyping, indicating that NUTM1 may be a candidate gene for cytogenetic rearrangements involving 15q (ref. 37). INF061 had both a BICD2-JAK2 and an ARHGAP32-CAPRIN1 fusion, as well as a truncation of the cohesin gene STAG2 (Supplementary  Table 17 ). Finally, INF070 carried a truncation in ARID1B, a member of the SWI/SNF chromatin-remodeling complex; truncations of this gene have been described in 7% of pediatric neuroblastoma 38 . Overall, the structural variations and CNAs differed substantially between MLL-R and non-MLL-R infant ALL, underscoring their differences in biology and clinical outcome 1 .
Epigenetic mutations in non-infant MLL-R leukemia
Although MLL rearrangements occur at a high frequency in infant ALL, such genetic lesions are also seen in older children with ALL or AML 39 . To compare the MLL-R mutational profiles for infants and older children, we performed whole-exome sequencing and SNP array analysis on 20 non-infant patients with MLL-R leukemia (7-19 years of age; 9 ALLs, 10 AMLs and 1 case of acute undifferentiated leukemia), as well as RNA-seq on 18 of 20 cases ( Supplementary  Figs. 4 and 40, and Supplementary Tables 9-11, 17, 31 and 32) . This analysis showed that the major clone in non-infant MLL-R leukemia harbored a significantly higher number of non-silent somatic SNVs and indels than in infant MLL-R ALL (mean of 6.5/case versus 1.3/case, P = 7.15 × 10 −5 ; for expressed genes, mean of 3.2/case versus 0.6/case, P = 1.6 × 10 −3 ; Fig. 4a and Supplementary Tables 33  and 34; see Supplementary Table 35 for a mutation summary for all three cohorts). Although there was a trend toward a lower basal mutation rate in infants in comparison to non-infants (P = 0.15), multiple linear regression analysis demonstrated that the significantly higher number of mutations in older children could not be attributed solely to the difference in the basal mutation rate (Supplementary Figs. 41 and 42, and Supplementary Note). This finding suggests that overt leukemia in older children with MLL rearrangements may require the acquisition of more cooperating mutations. As in infants with an MLL rearrangement, we identified activating mutations in tyrosine kinase-PI3K-RAS pathway genes in 50% of the non-infant leukemias, with recurrent mutations in FLT3 (n = 3), KRAS (n = 3) and NRAS (n = 3) and non-recurrent mutations in CBL, PIK3CD, PTPN11 and PPM1J, all of which were expressed at the RNA level ( Supplementary  Figs. 43 and 44, and Supplementary Tables 11 and 36) . In contrast to the mutation distribution in infant MLL-R ALL cases, the majority of the mutations in tyrosine kinase-PI3K-RAS pathway genes in the non-infant MLL-R leukemias were present in the major clone ( Supplementary Fig. 44 and Supplementary Table 25 ). This observation extended to all identified somatic exonic mutations, whereas, in infant MLL-R ALLs, these mutations were more commonly seen in minor clones (P < 0.0001; Supplementary Fig. 45 ). Non-infant MLL-R leukemias had a significantly higher number of CNAs as compared to infant MLL-R ALLs (average of 2.6/case versus 1.0/case, P = 0.0234; Supplementary Fig. 46 ). We noted deletions involving CDKN2A/CDKN2B in three of nine ALL cases (33%) but in none of the AML cases. None of the 20 non-infant MLL-R leukemias harbored a focal PAX5 lesion, which is in contrast to infant MLL-R ALLs, where PAX5 alterations were present in 5 of 22 cases (23%) ( Supplementary  Figs. 39, 44 and 47, and Supplementary Tables 37-39 ). RNA-seq identified two new in-frame non-MLL fusions: SETD2-CCDC12 (SJMLL009) and PABPC1L-YWHAB (SJMLL019). In addition, eight events identified in six cases resulted in out-of-frame fusions, one of which included MLL and four of which included MLL partner genes (Supplementary Table 17) . At the RNA level, we noted a unique gene expression signature correlating with age when comparing infants to older children with the MLL-AFF1 fusion (Supplementary Fig. 48 , and Supplementary Tables 40 and 41 ).
An interesting observation in non-infant MLL-R leukemias was the presence of somatic mutations in genes whose products have a direct role in epigenetic regulation. The dominant epigenetic regulatory proteins are encoded by 633 genes (Supplementary Table 42 ) 40 . If we excluded MLL, which was altered in every case, we identified somatic mutations in 11 epigenetic regulatory genes (CHD4, SETD2, CREBBP, L3MBTL3, ATR, KAT6A, KDM6A, NSD1, PARP8, SUPT3H and TET3) in 9 of 20 (45%) of the non-infant MLL-R leukemias ( Fig. 4b and  Supplementary Fig. 44 ). By contrast, only 3 of 22 (14%) infant MLL-R ALL cases harbored somatic mutations in epigenetic regulatory genes (P = 0.04; Fig. 4b) .
DISCUSSION
In this analysis of the genetic landscape of infant MLL-R ALL, we demonstrate that this highly aggressive leukemia contains remarkably few somatic mutations, having one of the lowest somatic coding mutation rates observed in a human cancer thus far 41, 42 . The only sequenced cancer that has a lower number of somatic coding mutations is pediatric low-grade glioma, a clinically indolent tumor 12 . The observed low mutational burden is consistent with the known oncogenic potency of MLL fusion proteins and the very short disease latency seen in infant MLL-R ALL, with some patients presenting with overt leukemia at birth. However, despite the low overall number of cooperating mutations, tyrosine kinase-PI3K-RAS signaling pathways were activated in almost half of infant MLL-R ALL cases. Although mutations in RAS genes have previously been described in MLL-R ALL [43] [44] [45] , we demonstrate for the first time, to our knowledge, recurrent activating npg A r t i c l e s mutations targeting the PI3K complex. Specifically, we found activating mutations in PIK3CA and PIK3R1 in 11% of the cases. The high frequency of activating mutations in tyrosine kinase-PI3K-RAS pathway genes underscores the biological cooperativity between MLL fusion proteins and enhanced signaling through these pathways [46] [47] [48] .
Although the allelic frequencies of the MLL chimeric genes indicated that these rearrangements are present in every leukemic cell, our detailed analysis of MAFs for the other identified somatic mutations suggest that they are often present in minor clones. For example, 65% of the activating tyrosine kinase-PI3K-RAS mutations had MAFs <30%, suggesting that they were present in minor diagnostic clones. In addition, although eight infant MLL-R ALL cases harbored two or more mutations in genes in these pathways, the MAF for each mutation was below 30% in six of these cases. Notably, all of the activating tyrosine kinase-PI3K-RAS pathway mutations were expressed, which was in contrast to other non-silent mutations in the discovery cohort, of which only 38% were expressed. Even more surprisingly, in our analysis of seven matched diagnostic and relapse infant MLL-R leukemia samples, five of which contained a diagnostic mutation in tyrosine kinase-PI3K-RAS pathways, we found that these mutant genes were maintained at relapse in two cases, decreased in frequency in one case and lost in two cases. Consistent with these observations, a recent report describing three paired samples from cases with MLL-AFF1 fusion demonstrated that two lost the clone carrying the RAS gene mutation at relapse 45 .
The presence of activating mutations in RAS genes in infant MLL-R leukemia has previously been suggested to be an independent predictor of a poor prognosis 43 . Although our cohort is small, our analysis suggested a trend toward a lower event-free survival and overall survival rate in cases with tyrosine kinase-PI3K-RAS pathway mutations, especially when the mutation was present at a MAF >30%. In contrast to the Interfant study 43 , within the cohort positive for the MLL-AFF1 fusion, those with an activating mutation were on average younger than those lacking a mutation. This age difference was even more pronounced when considering the cases positive for the MLL-AFF1 fusion with an activating mutation in the major clone, indicating that the presence of an activating mutation in these pathways may decrease the time required for the development of clinically overt disease. These data suggest that the coexistence of the MLL fusion protein with an activating mutation in tyrosine kinase-PI3K-RAS signaling pathways is not essential for either the establishment or maintenance of leukemia; however, the presence of these alterations likely confers a growth advantage. Our data also raise the possibility that the high degree of clonal heterogeneity observed in infant MLL-R ALL 49 might directly contribute to its poor prognosis, in that conventional ALL treatment regimens may not fully eliminate all clones, allowing the emergence of relapsed disease from a minor clone present at the time of diagnosis.
Interestingly, in non-infant MLL-R leukemias, most somatic mutations were found to reside within a single dominant clone. In addition, these cases harbored significantly more non-silent mutations than infant MLL-R leukemias, suggesting that MLL fusion genes require an increased number of cooperating mutations in older patients to generate overt disease. This raises the possibility that there may be a fundamental difference in the target cell of transformation, the microenvironment or both between infant and older patients. This hypothesis is further supported by the finding that non-infant MLL-R leukemias carry significantly more mutations in genes encoding epigenetic regulators than infant cases, suggesting that the target cell in infants may already have a chromatin state that is more permissive to transformation by the MLL gene rearrangement.
These data provide a unique look into the underlying molecular pathology of this highly aggressive pediatric leukemia. Our results suggest that, in infants, leukemia is initiated in a hematopoietic progenitor cell (HPC) that may have a different chromatic state than more mature HPCs and that, within this context, the MLL chimeric gene has a dominant role in establishing overtly leukemic cells. These cells gain few additional mutations during their proliferative expansion, although the frequent targeting of genes within tyrosine kinase-PI3K-RAS signaling pathways suggests that activation of this signaling can cooperate in leukemogenesis, albeit not to a level that results in the establishment of a dominant clone. Moreover, loss of the latter mutations at relapse in a number of patients suggests that specifically targeting these activating lesions will likely provide little therapeutic benefit. In contrast, the clear implication that the MLL fusion protein is a potent driver in this aggressive leukemia and that leukemic cells lack a high mutation rate raises the possibility that therapy directed toward the MLL fusion protein, or proteins required for its biological actions, might be a fruitful approach for targeted therapy in this aggressive leukemia.
ONLINE METhODS
Subjects. Paired-end whole-genome sequencing on diagnostic leukemia blasts and matched germline samples was performed on a discovery cohort of 22 infants with MLL-R ALL and 2 matched relapse samples (INF001R and INF002R) using the Illumina sequencing platform. The infants were treated at St. Jude Children's Research Hospital (Memphis, Tennessee, USA) and diagnosed during a period from 1992-2008. The cohort consisted of 10 cases with t(4;11) (MLL-AFF1 (AF4)), 5 cases with t(11;19) (MLL-MLLT1 (ENL)), 4 cases with t(10;11) (MLL-MLLT10 (AF10)) and 3 cases with t(9;11) (MLL-MLLT3 (AF9) Table 18 ). For 38 of the cases, a non-leukemic normal (germline) sample was available. INF059 and INF060 were identical twins, and a matched non-leukemic sample was only available for INF060; thus, this sample was also used as a germline sample for INF059.
In addition, five matched relapse infant MLL-R leukemia cases were investigated using either exome sequencing (SJINF033, SJINF065 and SJINF073) or targeted capture sequencing (SJINF042 and SJINF060). Two matched relapse samples from non-MLL-R infant cases also underwent whole-exome sequencing (SJINF039 and SJINF061).
Whole-exome sequencing was performed on 20 cases of non-infant MLL-R leukemia (1 acute undifferentiated leukemia, 9 ALL cases and 10 AML cases) (see Supplementary Table 31 for the clinical and genetic characteristics of these leukemias) and their matched normal, non-leukemic DNA sample. All patients were treated at St. Jude Children's Research Hospital. At diagnosis, 11q23 rearrangements were detected as described above.
Tumor and germline samples were obtained with informed consent using a protocol approved by the St. Jude Children's Research Hospital institutional review board. The study was approved by the institutional review boards of St. Jude Children's Research Hospital and Washington University.
Copy number analyses using Affymetrix SNP arrays. Of the 22 infant MLL-R ALL cases from the discovery cohort, 10 had copy number analyses performed using Affymetrix 500k SNP array as part of other studies and 12 had copy number data from the Affymetrix 6.0 SNP array data. In this study, we performed copy number analysis using the Affymetrix 6.0 SNP array for all samples in the validation cohort and for the non-infant MLL-R cases.
Illumina library construction for whole-genome sequencing. All methods for library construction and whole-genome DNA sequencing have been described previously 50, 51 . Detailed information regarding sequencing coverage is included in Supplementary Figure 1 and Supplementary Table 2.
Agilent liquid capture and library construction for whole-exome sequencing. Exon sequence was captured from 3 µg of genomic DNA using the Agilent SureSelect Human All Exon 50Mb kit (Agilent Technologies) following the manufacturer's instructions. After elution, cDNA libraries were sequenced (paired-end 2 × 101 cycles) on Illumina sequencers.
RNA sequencing. RNA-seq was performed on 21 diagnostic and 2 paired relapse cases from the discovery cohort (not INF007), on 12 diagnostic and 4 relapse MLL-R infant ALLs and 6 non-MLL-R infant leukemias from the validation cohort, and on 18 of 20 cases from the non-infant MLL-R cohort (Supplementary Tables 9-11 ). Total RNA was extracted with TRIzol (Ambion) according to the manufacturer's protocol. Total RNA (1 µg) was treated with DNase I (Ambion) at room temperature for 15 min, and phenolchloroform-isoamyl extraction and ethanol precipitation were performed. The integrity of the DNase I-treated RNA was analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies) before selection of poly(A) mRNA. Selection for poly(A) mRNA and subsequent cDNA synthesis were carried out using the Illumina TruSeq RNA sample preparation kit according to the manufacturer's protocol. cDNA was fragmented (200-bp peak) with a Covaris E210 ultrasonicator before library preparation using the Illumina TruSeq RNA sample preparation kit according to the manufacturer's protocol. Adaptorligated fragments were PCR amplified for ten cycles. The quality and size of the final library preparation were analyzed on an Agilent 2100 Bioanalyzer. Sequencing was performed on the Illumina HiSeq 2500 platform in rapid mode to generate paired-end 100-cycle reads. Putative in-frame fusions were validated by RT-PCR followed by Sanger sequencing. Primer sequences are available upon request.
of non-sequential pairs in RefSeq exons; and (iv) the AceView database flat file downloaded from UCSC representing transcripts constructed from human ESTs. The mapping results from (ii) to (iv) were translated to human reference genome coordinates. In addition, they were aligned using STAR 2.3.0 to the human GRCh37-lite reference sequence without annotations. A bam file was constructed by selecting the best alignment among the five mappings. Poorquality mappings were improved using SIM4, when possible, to generate the final bam file. Coverage was calculated using an in-house pipeline. Structural variation detection was carried out using CICERO, a novel algorithm that uses de novo assembly to identify structural variation in RNA-seq data (Y.L., T. Bo, M.R., J.E. and K.B. et al., unpublished data). Putative fusions were validated by RT-PCR.
Digital gene expression profiling. Transcript expression levels were estimated as fragments per kilobase of transcript per million mapped reads (FPKM); gene FPKMs were computed by summing the transcript FPKMs for each gene using Cuffdiff2 (refs. 56,57) . A gene was considered 'expressed' if its FPKM value was ≥0.5 on the basis of the distribution of FPKM gene expression levels. Genes that were not expressed in any sample were excluded from the final data matrix for downstream analysis. RNA expression profiles were analyzed using Qlucore Omics.
Targeted sequencing in the infant MLL-R and non-MLL-R validation cohorts. To determine the frequency of the identified mutations in a larger infant cohort, additional sequencing was performed for a total of 232 genes by Agilent Targeted Capture followed by Illumina sequencing (216 genes) or by PCR followed by Sanger sequencing (16 genes) in a validation cohort consisting of an additional 43 infant ALL cases, 25 of which harbored an MLL rearrangement. The 232 genes included in targeted sequencing were selected on the basis of the following criteria, including (i) if they were targeted by a genetic lesion (SNV, structural variation or focal CNA; ≤5 genes) in the infant MLL-R discovery cohort as determined by whole-genome sequencing (157/232 genes) or (ii) if they were annotated within a recurrently mutated pathway or if they had been described to be of importance for cancer (59 genes). This set of genes (n = 216) was analyzed by targeted capture. In addition, the coding exons from 16 genes were sequenced by Sanger sequencing (ABL1, AKT3, ALK, FOXO1, FOXO3, FOXO4, FOXO6, INPP5D, JAK2 , MET, PDGFRA, PDGFRB, PTEN, RAF1, RET and SYK), and putative SNVs and indel variants were detected by SNPdetector 58 . Non-silent sequence mutations were selected for validation by Sanger sequencing of both the tumor and matching normal samples (where available).
Experimental validation of somatic mutations and structural variants.
Validation of the identified somatic tier 1 SNVs was performed using PCR amplification of the leukemia and germline DNA samples followed by Sanger (SJINF010 and SJINF019) or 454-based (SJINF006-009, SJINF011-018 and SJINF020-022) sequencing. We validated the tier 1-4 mutations by array-based capture followed by Illumina-based sequencing for INF001-005. Structural variations were validated by PCR and subsequent Sanger sequencing on whole genome-amplified DNA or by capture-based methods.
The 454-based sequencing was performed as previously described 51 . Briefly, PCR products were subjected to library construction followed by 454 Titanium sequencing. Read sequences and quality scores were extracted with sffinfo (454 proprietary software), and sequences were aligned to NCBI Build 36 or 37 using SSAHA2 with the SAM output option. Alignments were imported to bam format using SAMtools. A SAMtools pileup file was generated, and read counts were determined by VarScan 59 . In the analysis of the 454 reads, a minimum base quality of 15 was required, with at least 20 reads aligned, to report the allele frequencies.
Oligonucleotide primers for genomic PCR were designed using the flanking sequences of each structural variation or SNV in Primer 3 (ref. 60) . For SJINF001-SJINF005, SJINF011R and SJINF002R, the structural variations were also validated using targeted capture followed by Illumina sequencing. Of the structural variations reported here, 77% have been experimentally validated.
Experimental validation of predicted in-frame fusion transcripts.
Predicted in-frame fusion transcripts were validated by RT-PCR followed by Sanger sequencing of the purified PCR products. Primer sequences are available upon request.
Clonal evolution analysis.
To decipher the potential clonal evolutionary path between the diagnostic and relapse tumor, we compared the MAFs of somatic SNVs detected at diagnosis and relapse. To have an accurate MAF readout, we performed deep sequencing using custom capture followed by Illumina sequencing on all tier 1-3 mutations detected by whole-genome sequencing in the trio of diagnostic, relapse and germline samples for cases SJINF001 and SJINF002. The median coverage of targets in the primary tumors SJINF001_D and SJINF002_D and in the relapse tumors SJINF001_R and SJINF002_R was 1,534×, 894×, 769× and 882×, respectively. The following criteria were used when assessing SNVs in the diagnostic tumor, requiring (i) that the mutant allele be missing from the matched germline sample and (ii) that the MAF be significantly different between the germline and diagnostic samples (Fisher's exact test P ≤ 0.05). SNVs located on the X or Y chromosomes or on chromosomal segments with CNAs were removed. The remaining tier 3 SNVs were used to perform normal mixture modeling using the mclust package (version 3.4.10) in R. The optimal model is determined by Bayesian information criterion (BIC).
FLT3 and PIK3R1-PIK3CA modeling. The structure for autoinhibited, inactive FLT3 kinase domain was used to model the Asn676Lys substitution (Protein Data Bank (PDB), 1RJB). The structures for phosphorylated (PDB, 2PSQ) and unphosphorylated (PDB, 2PVF) FGFR2 were used to model the mechanism of kinase activation 61, 62 . The Asn676Lys substitution was introduced into the FLT3 kinase domain structure and energy minimized with default parameters in FOLDX 63 . Images and structure alignments were performed in PyMOL. The structure for PIK3R1-PIK3CA was used to interpret the insertion and deletion mutation sites (PDB, 3HIZ) 64 ; this structure represents the inhibited state of the PIK3CA kinase domain. Prediction of disordered residues was performed by DISORED2 (ref. 65 ), and these residues were then visualized in PyMOL.
Clinical correlations. Association of the presence of an activating tyrosine kinase-PI3K-RAS signaling pathway mutation or the presence of a KRAS or NRAS mutation with clinical variables was tested using the exact χ 2 test. Event-free survival and overall survival distributions in different genetic groups were compared using the log-rank test. The cumulative incidence of any relapse was calculated according to the method of Kalbfleisch and Prentice and compared across genetic groups using Gray's test 66, 67 . We limited the outcome analyses to infants with MLL-R leukemias treated at St. Jude Children's Research Hospital (n = 33 for 10-year overall survival and 10-year event-free survival; n = 31 for risk of relapse).
Pathway analysis.
A genomic random interval (GRIN) 68 model was used as a null model to evaluate the statistical significance of the pattern of overlap of genomic lesions with the loci of individual genes, predefined sets of genes and each base-pair locus in the genome. The null model represented each lesion as an interval of fixed length and random location that might occur at any location along the chromosome with equal probability.
Other statistical analysis. Unless otherwise specified, statistical tests were performed using R (version 3.1.1). A two-sided Fisher's exact test was used to compare mutation frequencies in different patient groups. A two-sided Wilcoxon rank-sum test available in the R coin package (dealing with ties and reporting asymptotic P values) was used to compare the numbers of mutations, background mutation rates (BMRs) and CNAs in infant MLL-R ALL to those in non-infant MLL-R leukemias and to compare age in the two patient groups. A Kruskal-Wallis test was used to compare age among more than two patient groups. Two-sided tests for association using Spearman's ρ for mutations and age were performed using the R cor.test function.
DNA constructs and retrovirus production. Full-length wild-type FLT3, PIK3CA and PIK3R1 were amplified from human cDNA, and sequence variants (FLT3 D835Y (control), FLT3 D600H, FLT3 N676K, FLT3 D839G and FLT3 P934L; PIK3CA E542K (control) and PIK3CA H1047R (control); and PIK3R1 npg
